<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1422">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142644</url>
  </required_header>
  <id_info>
    <org_study_id>IUGR 1</org_study_id>
    <nct_id>NCT05142644</nct_id>
  </id_info>
  <brief_title>IUGR; Cause and Relationship</brief_title>
  <official_title>Intra Uterine Growth Retardation;Causes and Relationship</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrauterine growth retardation (IUGR) is a pregnancy complication that occurs in about 3-5%&#xD;
      of all pregnancies in Sweden. IUGR fetuses are at high risk of morbidity and death. The&#xD;
      method used in Sweden to detect IUGR is repeated measurements of the symphysis-fundus measure&#xD;
      (SF measure) of pregnant women.&#xD;
&#xD;
      Weight estimation with ultrasound is performed only on indication; stagnant or deplaning SF&#xD;
      dimensions or in the event of complications. Only high-risk pregnancies are followed with&#xD;
      repeated growth checks during pregnancy from the beginning.&#xD;
&#xD;
      There are likely benefits to detecting IUGR fetuses during pregnancy, but the effect is&#xD;
      disputed. A meta-analysis of randomized studies could not demonstrate any benefit from a&#xD;
      routine ultrasound in the third trimester.&#xD;
&#xD;
      The scientific purpose of this work is to evaluate the benefits of early detection and care&#xD;
      of SGA (small for time)/IUGR (growth-inhibited) fetuses and, if possible, to increase&#xD;
      knowledge about this patient group. The hope is that this will lead to a better opportunity&#xD;
      to personalize both preventive care and treatment of these women and children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Register-based cohort study. Population: All pregnancies in Stockholm from 2014 to&#xD;
      2017 A Composite outcome for the study is constructed and consists of at least one of the&#xD;
      following outcomes&#xD;
&#xD;
        1. HIE 2-3 (neonatal convulsions in the fetus after childbirth),&#xD;
&#xD;
        2. Intracranial hemorrhage,&#xD;
&#xD;
        3. Apgar score &lt; 4 at 5 minutes,&#xD;
&#xD;
        4. Arterial umbilical cord pH &lt; 7.10,&#xD;
&#xD;
        5. Intrauterine fetal death, 6)intrapartal death.&#xD;
&#xD;
      Inclusion: All pregnancies in Stockholm with a fetus, born between 2014 and 2017 and without&#xD;
      chromosomal abnormalities or other structural abnormalities, will be included in the project.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">October 30, 2021</completion_date>
  <primary_completion_date type="Actual">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perinatal outcome</measure>
    <time_frame>2014-2017</time_frame>
    <description>Does the perinatal outcome improve if fetal weight abnormalities are known before birth?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Group</measure>
    <time_frame>2014-2017</time_frame>
    <description>When divided into early- or late-diagnosed SGA (before and after week 32 of pregnancy) - does the difference persist?</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80000</enrollment>
  <condition>Intrauterine Growth Restriction</condition>
  <arm_group>
    <arm_group_label>Early / growth restriction</arm_group_label>
    <description>Intrauterine growth restriction with onset before 32 weeks of gestation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late growth restriction</arm_group_label>
    <description>Intrauterine growth restriction with onset after 32 weeks of gestation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrasound</intervention_name>
    <description>An extra ultrasound performed during pregnancy</description>
    <arm_group_label>Early / growth restriction</arm_group_label>
    <arm_group_label>Late growth restriction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All pregnant women in Stockholm during 2014-2017&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All pregnancies in Stockholm with a fetus, born between 2014 and 2017 and without&#xD;
             chromosomal abnormalities or other serious structural abnormalities, will be included&#xD;
             in the project.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancies with known chromosomal abnormalities or other serious structural&#xD;
             abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Eva Wiberg-Itzel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institute Sodersjukhuset Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eva Wiberg-Itzel</name>
      <address>
        <city>Stockholm</city>
        <zip>18239</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 21, 2021</last_update_submitted>
  <last_update_submitted_qc>November 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Eva Wiberg-Itzel</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>IUGR, SGA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

